Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

210.60 +1.10 (+0.53%)
Official Closing Price Updated: 7:00 PM EDT, Aug 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
84 85 Next >
Bristol Myers Squibb Further Diversifies Oncology Portfolio With Mega $8.4B Deal
SystImmune and Bristol Myers Squibb & Co (NYSE: BMY)  
Via Benzinga
AbbVie continues shopping spree with biotech buyout
While the diversifying AbbVie appears to be in a state of flux, there is one constant investors can depend on — the dividend. 
Via MarketBeat
Biotech Is Coming Back, Can The Run Last?
The rally can be attributed to lower interest rates and seasonal factors from the end of Q4 through January. But recently some major biopharmaceutical deals have supported the rally. 
Via Talk Markets
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Consolidated Communications Holdings, Inc. (Nasdaq - CNSL), Cerevel Therapeutics Holdings, Inc. (Nasdaq – CERE), ImmunoGen, Inc. (Nasdaq – IMGN), Graphite Bio, Inc.
From Brodsky & Smith LLC
Via GlobeNewswire
Is AbbVie Stock a Buy Now?
AbbVie's business could soon become more diversified. 
Via The Motley Fool
Decoding AbbVie's Options Activity: What's the Big Picture?
 
Via Benzinga
The 3 Best Cheap Stocks to Buy in December
Investors wanting to buy low and sell high should consider a position in one of these great companies whose shares have pulled back lately. 
Via InvestorPlace
4 Top Dividend Stocks Yielding More Than 4% to Buy Hand-Over-Fist This December
These companies offer above-average income streams that should continue rising. 
Via The Motley Fool
AbbVie Just Announced 2 Big Acquisitions: Is This Dividend King a No-Brainer Buy Right Now?
The big drugmaker went on a holiday shopping spree. 
Via The Motley Fool
3 Dividend Stocks You Can Safely Hold for Decades
These companies and their dividends are built to last. 
Via The Motley Fool
Better Dividend Stock: AbbVie vs. Medical Properties Trust
Which of these high-yield stocks has what it takes to keep raising their payouts? 
Via The Motley Fool
3 High-Yielding Dividend Stocks That Are Near Their 52-Week Lows
Buying these shares can provide you with some excellent recurring income while also diversifying your portfolio. 
Via The Motley Fool
AbbVie's on an Acquisition Binge. Could Your Favorite Biotech Stock Be Next?
Here's what's attracting lucrative buyout offers from big pharmaceutical companies these days. 
Via The Motley Fool
Healthcare Gems: 3 Essential Long-Term Stock Picks
Global healthcare spending reached a record $9 trillion in 2020. Catch the ongoing benefits with these three long-term healthcare stock picks. 
Via InvestorPlace
AbbVie's New $9B Neuroscience Space Deal Might Attract FTC Scrutiny, Analyst Signals
Wednesday, AbbVie Inc (NYSE: ABBV) agreed to acquire Cerevel Therapeutics Holdings Inc (NASDAQ: CERE) for a total equity value of approximately $8.7 billion, or $45 per share in cash, with the... 
Via Benzinga
Why Cerevel Therapeutics Stock Is Higher
Cerevel Therapeutics Holdings, Inc. 
Via Benzinga
Why Methode Electronics Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Methode Electronics, Inc (NYSE: MEI) fell sharply during Thursday’s session following weak quarterly earnings. 
Via Benzinga
Verint Reports Strong Earnings, Joins Semtech, Alphabet And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded mostly higher, with the Nasdaq Composite gaining more than 100 points on Thursday. 
Via Benzinga
Topics Stocks
Why Is Cerevel Therapeutics (CERE) Stock Up 12% Today?
Cerevel Therapeutics stock is climbing higher as CERE investors react to an $8.7 billion acquisition deal with AbbVie. 
Via InvestorPlace
Why Cerevel Therapeutics Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) jumped in pre-market trading after AbbVie Inc. (NYSE: ABBV) announced it will acquire the company for a total equity value of approximately... 
Via Benzinga
Which Stock Is More Likely to Help You Retire as a Millionaire: AbbVie or Eli Lilly?
There's no guarantee that either of these big pharma stocks can help you retire as a millionaire. But one has a clear edge. 
Via The Motley Fool
Looking for Dividend Growth in the New Year? 3 Magnificent Stocks to Buy Now.
These particular players look cheap right now. 
Via The Motley Fool
Why Cerevel Therapeutics Holdings Is Moving After-Hours
Cerevel Therapeutics Holdings Inc (NASDAQ: CERE) shares are trading higher in Wednesday's after-hours session after AbbVie Inc. (NYSE: ABBV) announced it will acquire the company for a total equity... 
Via Benzinga
7 High-Dividend Stocks to Buy for a Lifetime of Passive Income
These high-dividend stocks are among the biggest beneficiaries of current mega trends, and investors can leverage them for big gains. 
Via InvestorPlace
Small Cap, Big Potential: 3 Russell 2000 Stocks to Watch
The Russell 2000 index comprises small-cap companies, exposing investors to small organizations. Consider buying these Russell 2000 stocks. 
Via InvestorPlace
3 Stocks at the Forefront of Personalized Medicine Trend
Unveiling the impact of personalized medicine stocks, transforming patient care, and propelling market growth seamlessly 
Via InvestorPlace
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Hawaiian Holdings, Inc. (Nasdaq – HA), ImmunoGen, Inc. (Nasdaq – IMGN), Graphite Bio, Inc. (Nasdaq – GRPH), CapStar Financial Holdings, Inc. (Nasdaq – CSTR)
From Brodsky & Smith LLC
Via GlobeNewswire
ImmunoGen, AbbVie's $10B Deal Comes At 'Right Time' Analyst Says In Downgrade Note
AbbVie Inc (NYSE: ABBV) is acquiring ImmunoGen, Inc. (NASDAQ: IMGN) for around $ 
Via Benzinga
Doing Your Holiday Shopping? These Stocks Might Make Great Gifts
No matter which holiday you're planning gifts for, Christmas, Hanukkah, or some other occasion, there may be one great gift idea you haven't thought of yet. 
Via MarketBeat
Topics Bonds
AbbVie's Big Buy Of ImmunoGen Opens Doors For Potential Investment Gains
AbbVie's $10.1 billion acquisition of ImmunoGen, with its promising ovarian cancer drug, Elahere, signals a strategic move in the competitive cancer drug market. Investors anticipate market reactions,... 
Via Talk Markets
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
84 85 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.